[go: up one dir, main page]

ATE342969T1 - Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen - Google Patents

Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen

Info

Publication number
ATE342969T1
ATE342969T1 AT99911197T AT99911197T ATE342969T1 AT E342969 T1 ATE342969 T1 AT E342969T1 AT 99911197 T AT99911197 T AT 99911197T AT 99911197 T AT99911197 T AT 99911197T AT E342969 T1 ATE342969 T1 AT E342969T1
Authority
AT
Austria
Prior art keywords
ribozymes
inhibiting
expression
ccr5 receptor
provides
Prior art date
Application number
AT99911197T
Other languages
English (en)
Inventor
John J Rossi
Laurence Cagnon
Original Assignee
Hope City
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City filed Critical Hope City
Application granted granted Critical
Publication of ATE342969T1 publication Critical patent/ATE342969T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT99911197T 1998-03-11 1999-03-05 Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen ATE342969T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/038,741 US6100087A (en) 1998-03-11 1998-03-11 Ribozymes targeted to human CCR5 mRNA

Publications (1)

Publication Number Publication Date
ATE342969T1 true ATE342969T1 (de) 2006-11-15

Family

ID=21901629

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911197T ATE342969T1 (de) 1998-03-11 1999-03-05 Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen

Country Status (8)

Country Link
US (1) US6100087A (de)
EP (1) EP1062330B1 (de)
JP (1) JP4330797B2 (de)
AT (1) ATE342969T1 (de)
AU (1) AU2989799A (de)
CA (1) CA2323109A1 (de)
DE (1) DE69933653T2 (de)
WO (1) WO1999046372A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6261763B1 (en) * 1995-06-07 2001-07-17 Progenics Pharmaceuticals, Inc. Fluorescence resonance energy transfer screening assay for the identification of compounds that are capable of abrogating macrophage-tropic HIV-1 cell fusion
US7118859B2 (en) * 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6344545B1 (en) * 1996-06-14 2002-02-05 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US20040086528A1 (en) * 1996-06-14 2004-05-06 Progenics Pharmaceuticals, Inc. Uses of a chemokine receptor for inhibiting HIV-1 infection
US20040228869A1 (en) * 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US20080015348A1 (en) * 1998-12-16 2008-01-17 Progenics Pharmaceuticals, Inc. Nucleic acids encoding polypeptides of anti-CCR5 antibodies
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
GB2363608A (en) * 1999-05-21 2002-01-02 Oxford Biomedica Ltd Improved retroviral production
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7138119B2 (en) * 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7732193B2 (en) * 2001-09-13 2010-06-08 California Institute Of Technology Method for expression of small RNA molecules within a cell
US7737124B2 (en) * 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
AU2003281858A1 (en) * 2002-07-26 2004-02-23 Consejo Superior De Investigaciones Cientificas Multifunctional genetic constructions having a high capacity to inhibit the expression of ccr5 on the cell surface
EP1546178A4 (de) * 2002-07-31 2006-04-05 Hope City Adenovirales va1-pol-iii-expressionssystem zur rna-expression
EP1572956A2 (de) * 2002-08-01 2005-09-14 City of Hope Verfahren und kits zur synthese von sirna-expressionskassetten
ES2428628T3 (es) * 2002-12-12 2013-11-08 Novartis Vaccines And Diagnostics, Inc. Dispositivo y método para pruebas de sangre en línea usando biochips
US7943130B2 (en) 2003-12-11 2011-05-17 Yale University Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation
JP2008507255A (ja) 2004-03-12 2008-03-13 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
KR20080035653A (ko) * 2005-07-22 2008-04-23 프로제닉스 파머슈티컬스, 인코포레이티드 Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법
US7919583B2 (en) 2005-08-08 2011-04-05 Discovery Genomics, Inc. Integration-site directed vector systems
US20090074766A1 (en) * 2007-09-14 2009-03-19 Ketas Thomas J Methods of inhibiting HIV-2 infection
US8309791B2 (en) 2008-07-16 2012-11-13 Recombinectics, Inc. Method for producing a transgenic pig using a hyper-methylated transposon
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496698A (en) * 1992-08-26 1996-03-05 Ribozyme Pharmaceuticals, Inc. Method of isolating ribozyme targets
US5525468A (en) * 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
DE69739366D1 (de) * 1996-03-01 2009-05-28 Euroscreen Sa Aktive und inactive CC-Chemokinrezeptoren und Nukleinsäuremoleküle, die für diesen Rezeptor kodieren
AU3375697A (en) * 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
AU4055897A (en) * 1996-08-08 1998-02-25 Aaron Diamond Aids Research Center, The Hiv coreceptor mutants
US5939538A (en) * 1996-10-25 1999-08-17 Immusol Incorporated Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA
ES2233017T3 (es) * 1998-01-15 2005-06-01 King's College London Acidos nucleicos ribozimales que cortan ccr5 o cxcr4.

Also Published As

Publication number Publication date
WO1999046372A2 (en) 1999-09-16
DE69933653D1 (de) 2006-11-30
WO1999046372A3 (en) 1999-11-04
JP2002505876A (ja) 2002-02-26
US6100087A (en) 2000-08-08
AU2989799A (en) 1999-09-27
CA2323109A1 (en) 1999-09-16
EP1062330A2 (de) 2000-12-27
JP4330797B2 (ja) 2009-09-16
EP1062330B1 (de) 2006-10-18
DE69933653T2 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
ATE342969T1 (de) Ribozyme die fähig sind die expression des ccr5 rezeptor zu hemmen
DE69942485D1 (de) Nukleinsäureliganden mit hoher affinität zu dem c5-protein des komplementsystems
PT1355889E (pt) Derivados diamina triazole substituidos como inibidores de cinase
DE69403642D1 (de) 7-deazapurin modifizierte oligonukleotide
MXPA03000809A (es) Polimero de polisiloxano, procedimiento para su preparacion y su uso.
FI19992203L (fi) Menetelmä kauran beeta-glukaanin rikastamiseksi, menetelmällä saatava tuote sekä tuotteen käyttö
ATE550025T1 (de) Behandlung neurodegenerativer erkrankungen mittels intrakranialer freisetzung von small- interfering-rna (sirna)
ATE553128T1 (de) Anti-ngf-antikörper und verfahren zu ihrer verwendung
DE69637816D1 (de) Der expression von genen, welche spezifisch sind für die stärkebiosynthese
ATE290208T1 (de) Vorrichtung und verfahren zur ausführung elektrischer messungen an gegenständen
ATE481926T1 (de) Verfahren zum trainieren kognitive fähigkeiten
WO2002033116A3 (en) Nucleic acid ligands to the prostate specific membrane antigen
DE60126337D1 (de) Verfahren zum screenen für gpr40-liganden
NO20025241D0 (no) Katalysatorbirer og bÕret metallkatalysator, fremgangsmÕte for fremstilling, samt anvendelse
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
DE60031723D1 (de) Verfahren und system zum anbieten und erzeugen von accounts für potentielle benutzer eines instant-messaging-systems
DK1385993T3 (da) Fremgangsmåde til detektering og behandling af tuberøs sclerose kompleksrelaterede lidelser
DK1143917T3 (da) Antikonvulsive derivater egnet til behandling af posttraumatisk stresssygdom
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
TW200517910A (en) Order analysis system, order analysis method and order analysis program
ATE450003T1 (de) Komputergesteuerte verfahren und system zum implementieren von verteilten anwendungen
DE502004012272D1 (de) Kosmetisches oder therapeutisches kombinationspraparat
ATE325189T1 (de) Klonierungsverfahren durch multiple verdauung
SE0003126D0 (sv) Method of treatment
DE69903931D1 (de) Vorrichtung zur behandlung von wasser

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties